AVZO-1418/DB-1418 has received fast track designation from the FDA for patients with advanced, EGFR-mutant NSCLC following prior therapy with an EGFR TKI.

Avenzo Therapeutics and Duality Biotherapeutics have started dosing patients in a clinical study for a new cancer therapy involving the bispecific antibody-drug conjugate AVZO-1418/DB-1418.

Avenzo Therapeutics initiates Phase 1/2 clinical trial for AVZO-1418/DB-1418, a novel EGFR/HER3 bispecific antibody-drug conjugate aimed at treating advanced solid tumors.

Duality Biotherapeutics partner Avenzo Therapeutics receives FDA approval for AVZO-1418/DB-1418, a promising new cancer therapy targeting EGFR and HER3.

SHANGHAI, July 9, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the first patient has been dosed in the Phase 1...

SHANGHAI, July 8, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the first patient has been dosed in the Phase 1...

Oncology Update spotlights major moves: the European Commission approved KEYTRUDA SC across all adult indications with 1–2 minute administration, and Libtayo gained adjuvant approval in high-risk CSCC after C-POST showed a 68 percent reduction in recurrence or death, HR 0.32. Avenzo’s AVZO-1418 received FDA Fast Track for EGFR-mutated NSCLC post-TKI, while Bayer’s HYRNUO won US accelerated approval in HER2-mutated non-squamous NSCLC. Plus, Celcuity filed a gedatolisib RTOR NDA, BetaGlue’s YntraDose CTA cleared, ITM’s 177Lu-edotreotide NDA was accepted, and FDA aligned Alpha1H’s pivotal design for NMIBC.

Phase 1/2 first-in-human clinical study planned this year SHANGHAI and SAN DIEGO, May 22, 2025 /PRNewswire/ — Duality Biotherapeutics (“DualityBio”, HKEX:09606) partner Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for AVZO-1418/DB-1418, a …